No profile data available.
Cerus Corporation (CERS) is a healthcare company in the additional specific healthcare equipment industry, based in Concord, United States, with about 261 full-time employees.
It reported revenue of $206.13 million for fiscal year 2025, up 14.3% from fiscal year 2024, and net income of -$15.63 million. United States was its largest region in fiscal year 2025, with 61% of revenue. Its market capitalization was $463.51 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Cerus reported $206.13 million in revenue for fiscal year 2025, up 14.3% from $180.27 million in fiscal year 2024.
United States: 61% of revenue by region in fiscal year 2025, followed by Other Countries (29%).
$463.51 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional specific healthcare equipment) include Establishment Labs Holdings Inc. (ESTA), Dentsply Sirona Inc. (XRAY), InMode Ltd. (INMD), Avita Medical, Inc. (RCEL).